

## Typhoid Fever and Liver Enzyme Activity

**Muhammad M. Ibrahim<sup>1\*</sup>; Akbar Salihu<sup>2</sup> & Fatima Ibrahim Dugje<sup>3</sup>**

<sup>1</sup>Department of Microbiology, University of Maiduguri, Nigeria

<sup>2</sup>ART Unit, Infectious Disease Hospital, Kano, Nigeria

<sup>3</sup>Department of Medical Laboratory Science, University of Maiduguri; Nigeria

\*correspondence author: [mnistyle@yahoo.com](mailto:mnistyle@yahoo.com)

### ABSTRACT:

*Typhoid fever is a systemic infection caused by the Gram-negative bacillus Salmonella typhi and occasionally by Salmonella paratyphi. This study was carried out to assess the biochemical parameters AST, ALT and ALP in patients with Typhoid Fever. The study was designed to evaluate the serum liver enzymes' activities during the incidence of typhoid fever. The aminotransferases (AST and ALT) and alkaline phosphatase (ALP) activities were demonstrated using Reitman and Frankel method and King and Armstrong method respectively. A total of 200 subjects were studied, which was divided into 100 healthy individuals (controls) and 100 diagnosed typhoid fever patients. The results revealed a highly elevated levels of AST (25.6±17.6), ALT (22.5±8.8) and ALP (32.0±16.1) (p<0.05) observed in typhoid patients as compared to controls (1.0±1.7) (6.5±2.8) and (24.0±6.4) respectively. It could be noted from the findings of this study that there is a derangement of the liver enzyme values in typhoid patients. This study appears to have ample evidence based on the physiological and biochemical parameters in typhoid patients to help explain the influence of typhoid morbidity.*

**Keywords:** Salmonella typhi; Typhoid fever; Liver enzymes

### INTRODUCTION:

Typhoid fever is a systemic infection caused by the Gram-negative bacillus *Salmonella typhi* and occasionally by *Salmonella paratyphi* (Gienella, 1991). *Salmonella* are fermentative, facultative anaerobic, oxidase-negative Gram-negative rods. They are generally motile, aergenic, non-lactose fermenting, urease negative, citrate utilizing and acetyl methyl carbinol negative organisms. They cause localized infection of the gastrointestinal tract but can also multiply in the reticulo-endothelial system resulting in systemic infection and death. *Salmonella typhi* invade host cells by subverting host-cell signal transduction pathways and promoting cytoskeletal rearrangements. This results in the uptake of the microorganism via large vesicles or macropinosomes. To avoid the intracellular environment of the host, *Salmonella* invade macrophages, where they proliferate within a membrane-bound vacuole. The

incubation period for typhoid is longer than that for salmonellosis, usually one week. Historical accounts of typhoid written before the development of antimicrobial chemotherapy emphasized four main stages, lasting roughly one week each. The first week was characterized by rising fever, the second by rose spots, abdominal pain and splenomegaly and the third by the abdominal complications of haemorrhage or perforation followed by recovery in the fourth week (Stuart and Pullen, 1946).

The World Health Organization estimates there are 17 million typhoid cases annually and that these infections are associated with about 600 000 deaths (Pang *et al.*, 1998). Typhoid is predominantly a disease of the developing world: the incidence in the Far East is approximately 1000/100 000 (Sinha *et al.*, 1999, Lin *et al.*, 2000). In some developing countries the majority of cases are reported to be in the 5–14 year age



group, whereas other reports show a more even distribution but confirm that typhoid is an uncommon but serious infection in patients over 20 (Butler *et al.*, 1991, Lin *et al.*, 2000). In industrialized countries the majority of *S. typhi* infections are acquired abroad. Infection is acquired by ingestion of contaminated food and water or contact with a patient or carrier of the disease. It is restricted in host range to human beings, and there is no known animal reservoir. The incidence of typhoid is falling worldwide due to improvements in public health, such as provision of clean water and good sewage systems, but it still remains a major threat to human health.

Liver enzymes are proteins that help to speed up the rate of chemical reaction in the liver. Liver enzymes which are found in normal plasma or serum, can be divided into different groups. They are: aspartate amino transferase (AST), alanine amino transferase (ALT) together they are known as transaminases. Alkaline phosphatase (ALP) and gamma- glutamyl transferase (GGT) are known as cholestatic enzymes. Elevations of these enzymes can indicate liver disease (Perry, 1998).

Hepatitis due to typhoid fever is not only associated with other potentially life threatening extra-hepatic complications but relapse rate also is observed higher in patients with hepatic complications than those without hepatic involvement (WHO, 1997). This study is designed to determine the activities of liver enzymes in patients with typhoid fever. This can be achieved by comparing the results of liver enzyme levels obtained from typhoid fever patients with those of control individuals.

## MATERIALS AND METHOD

### STUDY AREA

The study was conducted at the University of Maiduguri Teaching Hospital, a tertiary care

hospital. It is situated in Maiduguri town, the capital of Borno State, Nigeria. It lies on latitude 11°N and longitude 12°E in the sudano-sahelian savanna zone with a dense population that are mostly crop farmers, fishermen, herdsman and traders (Udo 1978).

### STUDY SUBJECTS

A total of 200 subjects were recruited for the study. This consisted of 100 known typhoid fever patients attending University of Maiduguri Teaching Hospital and 100 apparently healthy individuals (controls).

### INCLUSION CRITERIA

- Informed consent of the subjects was sought for before sample collection.
- Sample collection was strictly base on clinically diagnosed typhoid patients.
- Clinically diagnosed typhoid fever patients of all age-groups were recruited for the study.
- Apparently healthy individuals without typhoid fever were selected as the control for the study.

### EXCLUSION CRITERIA

- Subjects who declined the consent will be excluded.
- All patients with confirm or diagnosed with liver disease or salmonella hepatitis are excluded because their liver enzyme levels are already distorted.

### ETHICAL CONSIDERATION

Ethical approval for the study was obtained from the ethical committee of the University of Maiduguri Teaching Hospital (UMTH).

### SAMPLE COLLECTION AND PROCESSING

Blood sample (2mls) was collected from the superficial vein of antecubital region. A tourniquet was applied to the upper arm to pause blood flow and the region was disinfected with 70% alcohol and allowed to dry. The blood was

drawn using sterile syringe and needle into a labeled plain vacutainer bottle. The blood was allowed to clot at room temperature and centrifuged at 4000 revolution per minute for 5 minutes. The serum was separated and transferred to a labeled plain sample container and stored in a refrigerator for further analysis (Cheesebrough 2006).

## ANALYTICAL METHODS

### Determination of Serum Aspartate Transaminase (AST) Activity

Serum AST activity was measured using colorimetric method as described by Reitman and Frankel, (1957).

#### Principle.

AST catalyses the transfer of amino group from aspartate to oxoglutarate forming glutamate and oxaloacetate when incubated at 27°C of pH 7.4 buffered substrate containing aspartate and alpha-oxoglutarate. The oxaloacetate reacts with 2,4 dinitrophenylhydrazine to form oxaloacetate hydrazone which in alkaline medium gives a red brown colour. The absorbance was read at 546nm.  $\alpha$ -Oxoglutarate +L- Aspartate L- glutamate+ Oxaloacetate Glutamate-Oxaloacetate (Schmidt, 1962).

### Determination of Serum Alanine Transaminase Activity (ALT):

The ALT activity was measured using the method described by Reitman and Frankel, (1957).

#### Principle

ALT catalyses the transfer of amino group from alanine to oxoglutarate forming glutamate and pyruvate when incubated at 27°C for 20mins at PH 7.4 buffered substrate containing alanine and alpha oxoglutarate. The pyruvate reacts with 2,4 dinitrophenylhydrazine to form pyruvate hydrazone which in alkaline medium gives red brown colour. This was measured spectrophotometrically at 546nm wavelength.  $\alpha$ -

Oxoglutarate +L-alanine L-glutamate+ pyruvate (Schmidt, 1962).

### Determination of Alkaline Phosphatase Activity (ALP)

Serum ALP activity will be estimated using King and Armstrong method as described by Balistreri and Shaw, (1987).

#### Principle

Serum ALP hydrolyses a colourless substrate of phenolphthalein monophosphate giving rise to phosphoric acid and phenolphthalein which at alkaline PH turns into a pink colour that can be determined photometrically (Klein, 1960).

## STATISTICAL ANALYSIS

Data generated will be analysed using SPSS software. The results of serum aspartate transferase, alanine transferase and alkaline phosphatase obtained from patients with typhoid fever will be compared with those from controls using student's t-test statistical method.

## RESULTS

The results obtained were expressed as mean  $\pm$  SD (standard deviation). A total of one hundred (100) diagnosed typhoid subjects participated in this study, fifty five (55) females and forty five (45) males. One hundred (100) apparently healthy individuals were recruited as control subjects. Probability values were determined at  $p \leq 0.05$ .

**Table 1** shows the mean  $\pm$  SD values of serum liver enzyme activities among typhoid patients. AST (25.6  $\pm$ 17.6), ALT (22.5 $\pm$ 8.8) and ALP (32.0 $\pm$ 16.1).

**Table 2** shows the comparison between the mean  $\pm$  SD values of serum liver enzyme activities of typhoid patient and that of the controls.

The levels of AST, ALT and ALP were 25.6 $\pm$ 17.6, 22.5 $\pm$ 8.8 and 32.0 $\pm$ 16.1 respectively, and are significantly elevated when compared to the controls; 8.1 $\pm$ 1.7, 6.5 $\pm$ 2.8 and 24.0 $\pm$ 6.4 respectively at  $p < 0.05$ .

**Table 1: Mean  $\pm$  SD of liver enzyme activities in patient with Typhoid Fever**

Parameters	Mean $\pm$ SD
AST (iu/l)	25.6 $\pm$ 17.6
ALT (iu/l)	22.5 $\pm$ 8.8
ALP (iu/l)	32.0 $\pm$ 16.1

p<0.05=significant    p>0.05=not significant

**Table 2 Comparison of mean $\pm$ SD of liver enzyme activities between typhoid patients and controls**

Parameters	Typhoid patients	Controls	p value
AST (iu/l)	25.6 $\pm$ 17.6	8.1 $\pm$ 1.7	0.00
ALT (iu/l)	22.5 $\pm$ 8.8	6.5 $\pm$ 2.8	0.00
ALP (iu/l)	32.0 $\pm$ 16.1	24.0 $\pm$ 6.4	0.00

p<0.05=significant    p>0.05=not significant

### DISCUSSION AND RECOMMENDATION:

In this study, the biochemical parameters, AST, ALT and ALP in the typhoid patients were found to be significantly elevated when compared with the control groups. This study tallies with the one reported by Al-shammaa et al, 2011 and Shamim et al, 2012. This severe hepatic involvement in Salmonella infection may be multifactorial, involving end toxin, local inflammatory and or host of immune reactions. SA salmonella endotoxin induced consumptive coagulopathy, damage to hepatocytes, arteritis, direct invasion of the hepatocytes by the organisms, immune complexes and consumption of complement are believed to contribute to hepatic insult. The clinical presentation and extent of hepatic dysfunction in typhoid fever would, therefore, depend upon these contributory factors and may or may not be associated with hepatomegaly typhoid.

This study has provided ample evidence on the activity of liver enzymes in typhoid patients, which reflects the influence of typhoid morbidity. It further shows that typhoid fever increases the rate of liver enzyme activity and as a result, could be useful in the diagnosis of typhoid fever. As such, it is advisable that routine evaluation of liver function test be considered as part of the management of typhoid patients to ensure proper control of hepatic function in the affected individuals.

### REFERENCES

- [1] Al-Shammam, N.M.J, Al-Wihalu,B.H, Abass, E.A.A. 2011. Effect of some enzymes activity in liver disease from patients of salmonella paratyphi A with Iraqi women. *Ibn haitham j. for pure & applied science.* vol 24 (2)



- [2] Arif N, Khan AA, Iqbal Z. 1990. Hepatic involvement with typhoid fever: A report of nine patients. *J Pak Med Assoc*, 40: 4-9.
- [3] Arora RK, Gupta A, Joshi NM, et al. 1992. Multidrug resistant typhoid fever. Study of  
a. an outbreak in Calcutta. *Indian Pediatr*, 29: 61-66.
- [4] Ayhan A, Gokoz A, Karacadag S, et al. 1973. The liver in typhoid fever. *Am J Gastroenterol*; 59: 141-146.
- [5] Brandborg LL, Goldman IR. 1990. Bacterial and miscellaneous infections of the liver in Zakim and Boyer eds *Hepatology* 2nd edition, *Saunders*; pp 1086-97.
- [6] Calva JJ, Palacios GR. 1986. Salmonella hepatitis: Detection of Salmonella antigens in the liver of patients with typhoid fever. *J Infect Dis*, 154: 373-374.
- [7] Colon AR, Cross DR, Tomer MA. 1975. Typhoid fever in children. *Pediatrics*; 56: 606-609.
- [8] Crump AJ, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. *Bull World Health Org*; 82:346-53.
- [9] Edelman R, Levine Myron M. 1986. Summary of an international workshop on typhoid fever. *Reviews of Infectious Diseases*; 8(3): 329-47.
- [10] EL-Newwih HM, Alamay ME, Reynolds TB. 1996. Salmonella hepatitis, analysis of 27 cases and comparison with acute viral hepatitis. *Hepatology* ; p24: 516-19.
- [11] Ferrecio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prenzel I, Black R, Mancuso T, Bulas D. 1984. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. *The Journal of Pediatrics*; 104(6): 899-901.
- [12] Giannella RA. 1991. Salmonella. In: Baron S, Jennings PM, eds. *Medical microbiology*. Churchill Livingstone: New York; 1991. p. 317-25.
- [13] Gitlin N. 1999. Bacterial and systemic infections. In Schiff's editor. *Disease of the liver* 8th ed. Lippincott William and Wilkins ; p 1549-58.
- [14] Gotuzzo E, Frisancho O, Sanchez J, Liendo G, Carillo C, Black RE, Morris JG. 1991. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area. *Archives of Internal Medicine*; 151: 381-2.
- [15] Gupta A. 1994. multi drug resistant typhoid fever in children: epidemiology and therapeutic approach. *Pediatr Infect Dis J*; 13:134-40.
- [16] Gupta SP, Gupta MS, Bharadwaj S, Chugh TD. 1985. Current clinical patterns of typhoid fever : A prospective study. *J Trop Med Hyg*, 88: 377-381.
- [17] Institute of Medicine. 1986. New vaccine development: establishing priorities. Vol.II. Diseases of importance in developing countries. Washington DC: National Academy Press; (Appendix D 14, p. 1-10).
- [18] Ivanoff B, Cordel J, Robert D, Fontanges R. 1980. Importance de la voie respiratoire dans la salmonellose expérimentale de la souris Balb/c. *Comptes Rendus de l'Académie des Sciences (Paris)*: 1271-4.
- [19] Ivanoff BN, Levine MM, Lambert PH. 1994. Vaccination against typhoid fever: present status. *Bulletin of the World Health Organization*; 72(6): 957-71.

- [20] Johnson AOK, Aderele WI. 1981. Enteric fever in childhood. *J Trop Med Hyg*; 84:29-35.
- [21] Khosla SN, Singh R, Singh GP, et al. 1988. The spectrum of hepatic injury in enteric fever. *Am J Gastroenterol*; 4: 413-416.
- [22] Khosla SN, Singh R, Singh GP, Trehan VK. 1988. The spectrum of hepatic injury in enteric fever. *Am J Gastroenterol*; 83: 413-16.
- [23] Khosla SN. 1990. Typhoid hepatitis. *Postgrad Med J*, 66: 923-925.
- [24] King, H, Amstrong, K. 1987. *Amer. J. Clin. Path*; 33:59
- [25] Klein, B., Read, P.A, Babson, L.A. 1960. *Clin. Chem*, 6,269-275.
- [26] Koul PB, Murali MV, Sharma PP, et al. 1991. Multidrug resistant *Salmonella typhi* infection: Clinical profile and therapy. *Indian Pediatr*, 28: 357-361.
- [27] Kumar A, Kapoor R, Chopra K, et al. 1989. Unusual hepatic manifestations in typhoid fever. *Clinical Pediatr*, 2: 99-100.
- [28] Levine MM, Black R, Lanata C, Chilean Typhoid Committee. 1982. Precise estimation of the number of chronic carriers of *Salmonella typhi* in Santiago, Chile, an endemic area. *The Journal of Infectious Diseases*; 146(6): 724-6.
- [29] Miller SI, Pegnes DA. 2000. *Salmonella* species, including *salmonella typhi* in Mandell GL, Bennett JE, Dolin R eds. *Principles and practice of infectious diseases* 5th ed, Churchill Livingstone, 2344-57.
- [30] Mishra S, Patwari AK, Anand VK, et al. 1991. A clinical profile of multidrug resistant typhoid fever. *Indian Pediatr*., 28: 1171-1174.
- [31] Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP, Ferrannini E (2005). Liver enzymes, the metabolic syndrome, and incident diabetes: The Mexico City diabetes study.
- [32] Osler W. 1899. Hepatic complication of typhoid fever. *Johns Hopkins Hosp Rep*; 8: 373-87.
- [33] Patel RB. 1993. Changing profile of enteric fever. Conference Abstract-1993, Bombay, Indian Academy of Pediatrics, p 39.
- [34] Perry IJ, Shaper AG (1998). Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.
- [35] Punjabi NH. 1998. Cost evaluation of typhoid fever in Indonesia. *Medical Journal of Indonesia*; 7(S): 90-3TR.
- [36] R.H.H Nelawan. 2007. Levoflavin: Today's choice for treatment of typhoid fever? An illustrated case report from Indonesia; pg 41-44.
- [37] Rajagopalan P, Kumar R, Malaviya AN. 1982. Immunological studies in typhoid fever. II. cell mediated immune responses and lymphocyte subpopulation in patients with typhoid fever. *Clin Exp Immunol*; 47: 269-274.
- [38] Ramachandran S, Godfrey JJ, Perera MVF. 1974. Typhoid hepatitis. *JAMA*; 230: 236-240.
- [39] Reitman, S, and Frankel, S. 1957. *Amer. J. Clin. Path*; 28:56
- [40] Rivai AR, et al. 1992. Clinical presentation of pediatric and adult typhoid fever subjects at the infectious diseases hospital (IDH) of Jakarta. In: Nelwan RHH,ed. *Typhoid fever profile, diagnosis and treatment in the 1990's*. FKUI Press: Jakarta. p. 85-94.

- [41] Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T, Santosham M, Black R. 2001. Typhoid fever in Bangladesh: implications for vaccination policy. *The Pediatric Infectious Disease Journal*; 20: 5214.
- [42] Schmidt, E., and Schmidt, F.W. 1963. *Enzym. Biol. Clin.* 3:1
- [43] Shamim, A, Shamim A, Hussain, B. 2012. Study of Biochemical Changes and elevated levels of enzymes in salmonella typhi infected patients in Pakistani population. *Int. J. Bioautomation*, 16(1), 33-42.
- [44] Siddeshi ER, Thapa BR, Sahni A, Mehta S. 1989. Enteric hepatitis. *Indian Pediatr*, 26: 512-513.
- [45] Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B, Rao M, Naficy A, Clemens J, Bhan MK. 1999. Typhoid fever in children aged less than 5 years. *Lancet*; 354: 734-737.
- [46] Stormoan MO, McIntyre PB, Morris J, Fasher B. 1997. Typhoid fever in children: diagnosis and therapeutic difficulties. *Pediatr Infect Dis J*; 16:713-14.
- [47] Thisyakorn U, Mansuwan P, Taylor DN. 1987. Typhoid and Paratyphoid fever in 192 hospitalized children in Thailand. *Am J Dis Child*, 141: 862-865. Volume 31-july 1994
- [48] Tomaraei SN, Singhi S. 1993. Hepatobiliary complications of enteric fever. *Indian Pediatr*;30: 721-724.
- [49] Typhoid fever (fact sheet N149) Geneva: World Health Organisation; 1997.